Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 13/20 | 0.63 |
| ▸ | PLG | P00747 | 6/20 | 0.63 |
| ▸ | PRSS1 | P07477 | 6/20 | 0.63 |
| ▸ | F2 | P00734 | 5/20 | 0.63 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.63 |
| ▸ | KLK1 | P06870 | 3/20 | 0.63 |
| ▸ | F12 | P00748 | 1/20 | 0.56 |
| ▸ | PLAT | P00750 | 4/20 | 0.48 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505347 | 0.80 | HTT (0.61) | PLAUPRSS1F2F12HTT | |
| Hydrochloric Acid SCHEMBL7342777 | 0.78 | PLAU (0.69) | PLAUPLGPRSS1F2KLKB1 | |
| SCHEMBL29941688 | 0.78 | PLAU (1.00) | PLAUPLGPRSS1F2KLKB1 | |
| SCHEMBL3370031 | 0.78 | PLAU (1.00) | PLAUPLGPRSS1F2KLKB1 | |
| Hydrogen Peroxide SCHEMBL9840257 | 0.77 | UGT2B7 (0.60) | HTTUGT2B7 | |
| Hydrogen Peroxide SCHEMBL9172508 | 0.77 | UGT2B7 (0.60) | HTTUGT2B7 | |
| SCHEMBL14445615 | 0.77 | PRSS1 (0.52) | PLAUPLGPRSS1F2KLKB1 | |
| SCHEMBL181347 | 0.77 | UGT2B7 (0.58) | HTTUGT2B7 | |
| SCHEMBL30031337 | 0.77 | UGT2B7 (0.58) | HTTUGT2B7 | |
| SCHEMBL10457062 | 0.76 | CYP2A6 (0.56) | UGT2B7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2023-08-03 | — | — | US | disclosed |
| US-10251878-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2019-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251878-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | PLAU 1328/4885PLG 1740/4885PRSS1 717/4885 |
| US-20230241054-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | PLAU 1328/4885PLG 1740/4885PRSS1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.